Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended budesonide treatment in IgA nephropathy after initial 9 months
ChiCTR2600133903Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in IgA nephropathy (IgAN), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Urine Total Protein/Creatinine Ratio (UPCR) at month 15. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2600133903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133903.